HC Wainwright Analysts Lower Earnings Estimates for ETON

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Eton Pharmaceuticals in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.09 per share for the quarter, down from their previous estimate of $0.12. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.14 EPS, FY2026 earnings at $0.85 EPS, FY2027 earnings at $1.13 EPS and FY2028 earnings at $1.28 EPS.

Separately, Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $10.02 on Friday. The business has a fifty day moving average price of $7.40 and a 200 day moving average price of $4.99. The company has a market cap of $258.92 million, a P/E ratio of -45.55 and a beta of 1.25. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $11.11.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ETON. Thompson Siegel & Walmsley LLC purchased a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at approximately $420,000. Aristides Capital LLC purchased a new position in Eton Pharmaceuticals in the second quarter worth approximately $658,000. Acadian Asset Management LLC increased its stake in Eton Pharmaceuticals by 13.7% during the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock worth $585,000 after acquiring an additional 18,898 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth $3,095,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Opaleye Management Inc. purchased 16,852 shares of the stock in a transaction dated Friday, October 4th. The shares were purchased at an average price of $6.77 per share, with a total value of $114,088.04. Following the transaction, the insider now owns 2,720,000 shares in the company, valued at $18,414,400. The trade was a 0.62 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 85,600 shares of company stock worth $462,674 over the last ninety days. Corporate insiders own 14.89% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.